Generic placeholder image

Current Pharmaceutical Design

Author(s): Beata Dubiel-Braszczok, Karolina Nowak, Aleksander Owczarek, Małgorzata Engelmann, Olga Gumkowska-Sroka and Przemysław J. Kotyla*

DOI: 10.2174/1381612828666220527141532

DownloadDownload PDF Flyer Cite As
Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab

Page: [2029 - 2037] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Rheumatoid arthritis (RA) represents the most frequent form of inflammatory arthritis, affecting approximately 1% of the population worldwide. The introduction of novel therapeutic strategies targeting proinflammatory cytokines (TNF-α and interleukin-6) revolutionized the treatment of RA. This kind of treatment, although effective in a substantial portion of patients, may potentially cause many side effects. Among them, cardiovascular safety is one of the main concerns.

Objectives: In the present study, we investigated the impact of treatment with anti-TNF-α and anti-IL-6 agents on heart function and levels of heart function biomarkers.

Methods: To measure this, we used cardiac function biomarkers, such as NT-pro Brain Natriuretic Peptide, mid regional pro-Atrial Natriuretic Peptide, Galectin-3, and Heart-Type Fatty Acid-Binding Protein and compared them to patients treated with methotrexate as well as healthy controls.

Results: Patients treated with biologics were characterized by low disease activity or were in remission. The disease activity in these groups was significantly lower than in the methotrexate group. All patients recruited for the study were characterized by normal heart function measured using echocardiography (EF>50%). With the exception of MR-proANP between tocilizumab and adalimumab (median: 1.01 vs. 0.49 nmol/L, p<0.05), we failed to observe any significant differences in biomarkers levels between groups treated with biologics. Contrary to this, patients on MTX showed higher NT-proBNP levels compared to adalimumab and healthy controls (p<0.05 for both). Striking differences have been shown in regard to H-FABP. The levels of these biomarkers were elevated in all biologics and the methotrexate group compared to healthy controls.

Conclusion: As this biomarker reflects potential heart injury, we suggest that heart damage proceeds in a continuous manner in RA patients despite effective treatment and attainment of remission/low disease activity. This finding, however, should be verified in a larger cohort of RA patients to ascertain if the routine assessment of H-FABP may be useful for the detection of patients with RA who are at risk of development of heart damage.

Keywords: Heart function, NT-proBNP, galectin-3, MR-proANP, H-FABP, biologics, rheumatoid arthritis.

[1]
Silvagni E, Giollo A, Sakellariou G, et al. One year in review 2020: Novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2020; 38(2): 181-94.
[PMID: 32213264]
[2]
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: A meta-analysis of observational studies. Ann Rheum Dis 2012; 71(9): 1524-9.
[http://dx.doi.org/10.1136/annrheumdis-2011-200726] [PMID: 22425941]
[3]
Hartman MHT, Groot HE, Leach IM, Karper JC, van der Harst P. Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med 2018; 28(6): 369-79.
[http://dx.doi.org/10.1016/j.tcm.2018.02.003] [PMID: 29519701]
[4]
Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35(3): 537-44.
[http://dx.doi.org/10.1016/S0735-1097(99)00600-2] [PMID: 10716453]
[5]
Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109(13): 1594-602.
[http://dx.doi.org/10.1161/01.CIR.0000124490.27666.B2] [PMID: 15023878]
[6]
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003; 107(25): 3133-40.
[http://dx.doi.org/10.1161/01.CIR.0000077913.60364.D2] [PMID: 12796126]
[7]
Mavrogeni S, Dimitroulas T, Sfikakis PP, Kitas GD. Heart involvement in rheumatoid arthritis: Multimodality imaging and the emerging role of cardiac magnetic resonance. Semin Arthritis Rheum 2013; 43(3): 314-24.
[http://dx.doi.org/10.1016/j.semarthrit.2013.05.001] [PMID: 23786873]
[8]
Kotyla PJ, Owczarek A, Rakoczy J, Lewicki M, Kucharz EJ, Emery P. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: Assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol 2012; 39(4): 701-6.
[http://dx.doi.org/10.3899/jrheum.110751] [PMID: 22337242]
[9]
Harrold LR, Griffith J, Zueger P, et al. Longterm, real-world safety of adalimumab in rheumatoid arthritis: Analysis of a prospective US-based registry. J Rheumatol 2019.
[PMID: 31371657]
[10]
Kotyla PJ. Bimodal function of anti-TNF treatment: Shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci 2018; 19(6): 19.
[http://dx.doi.org/10.3390/ijms19061739] [PMID: 29895751]
[11]
Castañeda S, Nurmohamed MT, González-Gay MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016; 30(5): 851-69.
[http://dx.doi.org/10.1016/j.berh.2016.10.006] [PMID: 27964792]
[12]
Castaneda S, Gonzalez-Juanatey C, Gonzalez-Gay MA. Inflammatory arthritis and heart disease. Curr Pharm Des 2018; 24(3): 262-80.
[http://dx.doi.org/10.2174/1381612824666180123102632] [PMID: 29359662]
[13]
Xu L, Yan J, Zhang F, et al. Use of inflammatory biomarkers and real-time cardiac catheterisation to evaluate the left ventricular diastolic function in patients with diastolic heart failure. Heart Lung Circ 2020; 30(3): 396-403.
[PMID: 32736962]
[14]
Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004; 45(2): 183-93.
[http://dx.doi.org/10.1536/jhj.45.183] [PMID: 15090695]
[15]
Gabriel AS, Martinsson A, Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: Their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med 2004; 15(8): 523-8.
[http://dx.doi.org/10.1016/j.ejim.2004.07.013] [PMID: 15668089]
[16]
Han X, Zhang S, Chen Z, et al. Cardiac biomarkers of heart failure in chronic kidney disease. Clin Chim Acta 2020; 510: 298-310.
[http://dx.doi.org/10.1016/j.cca.2020.07.040] [PMID: 32710942]
[17]
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[18]
Picard MH, Adams D, Bierig SM, et al. American society of echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr 2011; 24(1): 1-10.
[http://dx.doi.org/10.1016/j.echo.2010.11.006] [PMID: 21172594]
[19]
Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66(5): 670-5.
[http://dx.doi.org/10.1136/ard.2006.062497] [PMID: 17158824]
[20]
Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156(2): 336-41.
[http://dx.doi.org/10.1016/j.ahj.2008.02.025] [PMID: 18657665]
[21]
Al-Aly Z, Pan H, Zeringue A, et al. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011; 157(1): 10-8.
[http://dx.doi.org/10.1016/j.trsl.2010.09.005] [PMID: 21146146]
[22]
Ridker PM, MacFadyen JG, Glynn RJ, Bradwin G, Hasan AA, Rifai N. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: Secondary analyses from the cardiovascular inflammation reduction Trial. Eur Heart J 2020; 41(31): 2952-61.
[http://dx.doi.org/10.1093/eurheartj/ehaa160] [PMID: 32221587]
[23]
Castañeda S, Remuzgo-Martínez S, López-Mejías R, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol 2019; 37(3): 465-73.
[PMID: 30418124]
[24]
Wenzl FA, Ambrosini S, Mohammed SA, et al. Inflammation in metabolic cardiomyopathy. Front Cardiovasc Med 2021; 8742178
[http://dx.doi.org/10.3389/fcvm.2021.742178] [PMID: 34671656]
[25]
Rudominer RL, Roman MJ, Devereux RB, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009; 60(1): 22-9.
[http://dx.doi.org/10.1002/art.24148] [PMID: 19116901]
[26]
Bradham W, Ormseth MJ, Elumogo C, et al. Absence of fibrosis and inflammation by cardiac magnetic resonance imaging in rheumatoid arthritis patients with low to moderate disease activity. J Rheumatol 2018; 45(8): 1078-84.
[http://dx.doi.org/10.3899/jrheum.170770] [PMID: 29657146]
[27]
Løgstrup BB, Deibjerg LK, Hedemann-Andersen A, Ellingsen T. Left ventricular function in treatment-naive early rheumatoid arthritis. Am J Cardiovasc Dis 2014; 4(2)(Suppl. 2): 79-86.
[http://dx.doi.org/10.1136/annrheumdis-2014-eular.1865] [PMID: 25006535]
[28]
Sitia S, Tomasoni L, Cicala S, et al. Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. Int J Cardiol 2012; 160(1): 8-14.
[http://dx.doi.org/10.1016/j.ijcard.2011.03.012] [PMID: 21450355]
[29]
George J, Mackle G, Manoharan A, Khan F, Struthers AD. High BNP levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities: A prospective case-control study. Int J Cardiol 2014; 172(1): e116-8.
[http://dx.doi.org/10.1016/j.ijcard.2013.12.119] [PMID: 24433615]
[30]
Peters MJ, Welsh P, McInnes IB, et al. Tumour necrosis factor alpha blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: Results from a prospective cohort study. Ann Rheum Dis 2010; 69(7): 1281-5.
[http://dx.doi.org/10.1136/ard.2009.119412] [PMID: 19934107]
[31]
Keyzer JM, Hoffmann JJ, Ringoir L, Nabbe KC, Widdershoven JW, Pop VJ. Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care. Clin Chem Lab Med 2014; 52(9): 1341-6.
[http://dx.doi.org/10.1515/cclm-2013-0791] [PMID: 24781675]
[32]
Yokoe I, Kobayashi H, Kobayashi Y, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol 2018; 47(5): 364-70.
[http://dx.doi.org/10.1080/03009742.2017.1418424] [PMID: 29804492]
[33]
Welsh P, Tuckwell K, McInnes IB, Sattar N. Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis 2016; 254: 167-71.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.10.016] [PMID: 27744141]
[34]
Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J 2008; 72(1): 109-14.
[http://dx.doi.org/10.1253/circj.72.109] [PMID: 18159110]
[35]
Niizeki T, Takeishi Y, Arimoto T, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J 2005; 69(8): 922-7.
[http://dx.doi.org/10.1253/circj.69.922] [PMID: 16041160]
[36]
Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 2005; 11(7): 504-9.
[http://dx.doi.org/10.1016/j.cardfail.2005.04.025] [PMID: 16198245]
[37]
Ntusi NAB, Piechnik SK, Francis JM, et al. Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: Insights from CMR T1 mapping. JACC Cardiovasc Imaging 2015; 8(5): 526-36.
[http://dx.doi.org/10.1016/j.jcmg.2014.12.025] [PMID: 25890584]
[38]
Baran A, Świderska M, Bacharewicz-Szczerbicka J, Myśliwiec H, Flisiak I. Serum fatty acid-binding protein 4 is increased in patients with psoriasis. Lipids 2017; 52(1): 51-60.
[http://dx.doi.org/10.1007/s11745-016-4211-4] [PMID: 27864793]
[39]
Ohshima S, Kuchen S, Seemayer CA, et al. Galectin 3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003; 48(10): 2788-95.
[http://dx.doi.org/10.1002/art.11287] [PMID: 14558084]
[40]
Chen A, Hou W, Zhang Y, Chen Y, He B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. Int J Cardiol 2015; 182: 168-70.
[http://dx.doi.org/10.1016/j.ijcard.2014.12.137] [PMID: 25577755]
[41]
Schindler EI, Szymanski JJ, Hock KG, Geltman EM, Scott MG. Short- and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults. Clin Chem 2016; 62(2): 360-6.
[http://dx.doi.org/10.1373/clinchem.2015.246553] [PMID: 26546635]
[42]
Dong R, Zhang M, Hu Q, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 2018; 41(2): 599-614.
[PMID: 29207027]
[43]
Hu Y, Yéléhé-Okouma M, Ea HK, Jouzeau JY, Reboul P. Galectin-3: A key player in arthritis. Joint Bone Spine 2017; 84(1): 15-20.
[http://dx.doi.org/10.1016/j.jbspin.2016.02.029] [PMID: 27238188]
[44]
Straub RH, Ehrenstein B, Günther F, et al. Increased extracellular water measured by bioimpedance and by increased serum levels of atrial natriuretic peptide in RA patients-signs of volume overload. Clin Rheumatol 2017; 36(5): 1041-51.
[http://dx.doi.org/10.1007/s10067-016-3286-x] [PMID: 27112146]
[45]
Tan AC, Jansen TL, Termond EF, et al. Kinetics of atrial natriuretic peptide in young and elderly subjects. Eur J Clin Pharmacol 1992; 42(4): 449-52.
[PMID: 1387608]
[46]
Kotyla P, Jankiewicz-Ziobro K, Owczarek A, Kucharz EJ. Etanercept increases tumor necrosis factor-alpha level but not sFas level in patients with rheumatoid arthritis. Isr Med Assoc J 2015; 17(1): 14-8.
[PMID: 25739170]
[47]
Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124(1): 177-85.
[http://dx.doi.org/10.1378/chest.124.1.177] [PMID: 12853521]
[48]
Kayakabe K, Kuroiwa T, Sakurai N, et al. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012; 51(9): 1639-43.
[http://dx.doi.org/10.1093/rheumatology/kes094] [PMID: 22596214]